Phosphatidylserine / lipid-P Cancer Research Results

PS, Phosphatidylserine: Click to Expand ⟱
Features:

Phosphatidylserine (PS) — an anionic membrane phospholipid (glycerophospholipid) enriched in brain and inner-leaflet plasma membranes. Supplement sources: soy-derived PS (modern) and historically bovine cortex PS (largely discontinued in many markets).

Primary mechanisms (conceptual rank):
1) Membrane signaling scaffold (protein kinase docking; synaptic membrane function)
2) Apoptotic “eat-me” signal when externalized (PS flip to outer leaflet) → immunologic clearance axis
3) Stress-axis modulation (HPA/cortisol context; cognitive-stress performance literature)
4) Neurotransmission support (cholinergic/synaptic plasticity coupling; indirect)

Bioavailability / PK relevance: Oral PS is digested to lyso-phospholipids/fatty acids and re-esterified; effects are typically chronic (weeks) and reflect membrane remodeling and signaling adaptation rather than acute pharmacology.

In-vitro vs oral exposure: Direct anti-cancer cytotoxicity from PS exposure is generally not a physiologic oral-supplement mechanism; many tumor-PS findings relate to surface PS biology and targeting strategies rather than dietary PS.

Clinical evidence status: Human data strongest for cognitive/stress outcomes (modest; mixed by age/product/dose). Oncology relevance is mainly mechanistic/targeting-adjacent (preclinical).

PS is a negatively charged phospholipid found predominantly in the inner leaflet of cell membranes, especially in neurons.
-Clinical trials show potential benefits in:
-Improving memory and attention in elderly subjects
-Slowing cognitive decline in early AD or mild cognitive impairment (MCI)
-PS is thought to enhance cell membrane function, neurotransmission, and possibly reduce oxidative stress.


Phosphatidylserine (PS) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 PS externalization (apoptotic / tumor-surface PS) ↑ surface PS (context-dependent) ↑ during apoptosis P/R Immune recognition / clearance cue Many tumors display elevated outer-leaflet PS (often due to stress, hypoxia, ROS, therapy); key for PS-targeting strategies (antibodies/ligands), not necessarily oral PS.
2 Tumor immune microenvironment (PS-mediated immunosuppression) ↑ immunosuppressive signaling (context-dependent) ↔ R/G “Quiet” clearance phenotype Outer PS can bias toward tolerogenic phagocytosis (TAMs/MDSCs) and reduced anti-tumor immunity (model-dependent).
3 Membrane signaling scaffold (PKC/AKT docking; lipid rafts) ↔ / ↑ (context-dependent) ↑ physiologic signaling support G Signal transduction modulation PS provides anionic docking sites for kinases; in cancer this can support survival signaling depending on pathway context.
4 Apoptosis execution (intrinsic pathway) ↑ (secondary to stress/therapy) ↑ R/G Cell death progression PS is a marker and mediator of apoptotic clearance rather than a primary trigger from supplementation.
5 ROS ↑ → PS flip (context-dependent) ↑ → PS flip (high stress) P/R Oxidative stress coupling ROS and lipid peroxidation can promote membrane asymmetry loss and PS externalization.
6 NRF2 axis ↔ ↔ R/G No primary modulation PS is not a canonical NRF2 modulator; any linkage is indirect via oxidative stress state.
7 Ferroptosis (membrane lipid peroxidation) ↔ / ↑ PS flip (secondary) ↔ R/G Peroxidation-driven membrane stress Not a primary PS mechanism; lipid peroxidation can destabilize membrane asymmetry and expose PS.
8 HIF-1α / hypoxia stress coupling ↑ surface PS (hypoxia-linked; context-dependent) ↔ G Stress phenotype marker Hypoxia/therapy stress can increase tumor-surface PS; largely a state-marker and targetable feature.
9 Ca²⁺-dependent scramblase / flippase balance ↑ PS externalization (stress-dependent) ↑ PS externalization (stress-dependent) P/R Membrane asymmetry regulation Elevated intracellular Ca²⁺ activates scramblases and can promote PS exposure; relevant in apoptosis/ER stress models.
10 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Supplement vs targeting mismatch Oral PS mainly supports normal-cell membrane/synaptic function; oncology relevance is primarily via tumor-surface PS targeting, not dietary PS delivery.

TSF legend:
P: 0–30 min (membrane asymmetry/ion effects)
R: 30 min–3 hr (stress signaling + apoptosis progression)
G: >3 hr (membrane remodeling / phenotype outcomes)


Phosphatidylserine (PS) — AD relevance: A brain-enriched phospholipid linked to synaptic membrane function and signaling; supplementation is used for cognitive symptoms and stress-related memory performance. AD/MCI relevance is mainly supportive (synaptic function + stress-axis), not disease-modifying.

Primary mechanisms (conceptual rank):
1) ↑ Synaptic membrane function / signaling efficiency (plasticity support)
2) ↓ Stress-axis overactivation (cortisol/HPA modulation; context-dependent)
3) ↑ Cholinergic neurotransmission support (indirect)
4) ↓ Neuroinflammation / oxidative burden (secondary; modest evidence)

Bioavailability / PK relevance: Effects typically require weeks of daily intake (remodeling/adaptation). Outcomes depend on dose, source, baseline diet, and cognitive status.

Clinical evidence status: Small human trials show modest benefits in some groups (older adults, stress-related impairment, MCI signals); overall mixed and not definitive for AD progression.

Phosphatidylserine (PS) — AD / Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 Synaptic membrane function / plasticity ↑ G Improved signaling efficiency PS supports membrane microdomains and protein docking needed for synaptic transmission; benefits are typically chronic/adaptive.
2 Stress-axis (HPA/cortisol) ↓ (context-dependent) R/G Reduced stress-related cognitive impairment Best described in stress-performance contexts; relevance to AD depends on stress burden and comorbidity.
3 Cholinergic signaling ↑ (indirect) R/G Neurotransmission support Supportive mechanism; not equivalent to AChE inhibitor pharmacology.
4 ROS ↔ / ↓ (secondary) P/R Oxidative burden moderation Not a primary antioxidant; effects are indirect via improved membrane/mitochondrial resilience.
5 NRF2 axis ↔ R/G No primary modulation Any NRF2 linkage is indirect and model-dependent.
6 Neuroinflammation ↔ / ↓ (secondary) R/G Inflammatory tone modulation Reported in some models; generally not the dominant mechanism for PS supplementation.
7 Ca²⁺ homeostasis / excitotoxic vulnerability ↔ / stabilized (indirect) P/R Membrane/ion-channel environment support Membrane composition can influence channel/receptor function; treat as secondary unless specific Ca²⁺ data exist.
8 Aβ / tau pathology ↔ (limited evidence) G Not primary axis PS is not established to directly reduce amyloid/tau burden in humans.
9 Clinical Translation Constraint ↓ (constraint) — Modest, non–disease-modifying Benefits (when present) are modest and require sustained dosing; product source/dose and baseline status drive variability.

TSF legend:
P: 0–30 min (membrane/ion interactions)
R: 30 min–3 hr (acute signaling shifts)
G: >3 hr (remodeling/adaptation outcomes)
lipid-P, lipid peroxidation: Click to Expand ⟱
Source:
Type:
Lipid peroxidation is a chain reaction process in which free radicals (often reactive oxygen species, or ROS) attack lipids containing carbon-carbon double bonds, especially polyunsaturated fatty acids. This attack results in the formation of lipid radicals, peroxides, and subsequent breakdown products.
Lipid peroxidation can cause damage to cell membranes, leading to increased permeability and disruption of cellular functions. This damage can initiate a cascade of events that may contribute to carcinogenesis.
The byproducts of lipid peroxidation, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), can form adducts with DNA, leading to mutations. These mutations can disrupt normal cellular processes and contribute to the development of cancer.
Lipid peroxidation damages cell membranes, disrupts cellular functions, and can trigger inflammatory responses. It is a marker of oxidative stress and is implicated in many chronic diseases.

Negative Prognostic Indicator: In many cancers, high levels of lipid phosphates, particularly S1P, are associated with poor prognosis, indicating a more aggressive tumor phenotype and potential resistance to therapy.
Mixed Evidence: The prognostic significance of lipid phosphates can vary by cancer type, with some studies showing that their expression may not always correlate with adverse outcomes.
Scientific Papers found: Click to Expand⟱
3914- PS,    Soybean-Derived Phosphatidylserine Improves Memory Function of the Elderly Japanese Subjects with Memory Complaints
- Trial, AD, NA
*memory↑, *cognitive↑, *lipid-P↓, *antiOx↑, *Inflam↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   lipid-P↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   memory↑, 1,  
Total Targets: 5

Scientific Paper Hit Count for: lipid-P, lipid peroxidation
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:341  Target#:453  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page